# Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

> **NCT00086580** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 335 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** FluCAM [Fludara + Campath]
- **BIOLOGICAL:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00086580
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086580, "Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00086580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*